Patents by Inventor Kathrin Gnoth

Kathrin Gnoth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-isoAsp7 amyloid ? (A?) antibodies and uses thereof
    Patent number: 11703511
    Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: July 18, 2023
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Anke Piechotta, Kathrin Gnoth, Holger Cynis, Jens-Ulrich Rahfeld, Stephan Schilling, Hans-Ulrich Demuth
  • ANTI- ISOASP7 AMYLOID ß (Aß) ANTIBODIES AND USES THEREOF
    Publication number: 20200264197
    Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 20, 2020
    Inventors: Anke PIECHOTTA, Kathrin GNOTH, Holger CYNIS, Jens-Ulrich RAHFELD, Stephan SCHILLING, Hans-Ulrich DEMUTH
  • Uses of antibodies directed against amyloid-?
    Patent number: 9676843
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 13, 2017
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer